Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CLDN18.2 positive
i
Other names:
CLDN18, Claudin-18, Surfactant, Pulmonary Associated Protein J, Surfactant Associated 5, SFTA5, SFTPJ
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
51208
Related biomarkers:
Expression
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
CLDN18.2 positive
Gastric Cancer
CLDN18.2 positive
Gastric Cancer
CT041
Sensitive: C2 – Inclusion Criteria
CT041
Sensitive
:
C2
CT041
Sensitive: C2 – Inclusion Criteria
CT041
Sensitive
:
C2
CLDN18.2 positive
Solid Tumor
CLDN18.2 positive
Solid Tumor
MIL93
Sensitive: C2 – Inclusion Criteria
MIL93
Sensitive
:
C2
MIL93
Sensitive: C2 – Inclusion Criteria
MIL93
Sensitive
:
C2
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CT041
Sensitive: C2 – Inclusion Criteria
CT041
Sensitive
:
C2
CT041
Sensitive: C2 – Inclusion Criteria
CT041
Sensitive
:
C2
CLDN18.2 positive
Gastric Cancer
CLDN18.2 positive
Gastric Cancer
AB011
Sensitive: C2 – Inclusion Criteria
AB011
Sensitive
:
C2
AB011
Sensitive: C2 – Inclusion Criteria
AB011
Sensitive
:
C2
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CMG901
Sensitive: C2 – Inclusion Criteria
CMG901
Sensitive
:
C2
CMG901
Sensitive: C2 – Inclusion Criteria
CMG901
Sensitive
:
C2
CLDN18.2 positive
Gastric Cancer
CLDN18.2 positive
Gastric Cancer
CMG901
Sensitive: C2 – Inclusion Criteria
CMG901
Sensitive
:
C2
CMG901
Sensitive: C2 – Inclusion Criteria
CMG901
Sensitive
:
C2
CLDN18.2 positive
Pancreatic Ductal Adenocarcinoma
CLDN18.2 positive
Pancreatic Ductal Adenocarcinoma
CT041
Sensitive: C3 – Early Trials
CT041
Sensitive
:
C3
CT041
Sensitive: C3 – Early Trials
CT041
Sensitive
:
C3
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
AB011
Sensitive: C3 – Early Trials
AB011
Sensitive
:
C3
AB011
Sensitive: C3 – Early Trials
AB011
Sensitive
:
C3
CLDN18.2 positive
Gastric Cancer
CLDN18.2 positive
Gastric Cancer
CLDN18.2-targeted CAR-T immunotherapy
Sensitive: D – Preclinical
CLDN18.2-targeted CAR-T immunotherapy
Sensitive
:
D
CLDN18.2-targeted CAR-T immunotherapy
Sensitive: D – Preclinical
CLDN18.2-targeted CAR-T immunotherapy
Sensitive
:
D
CLDN18.2 positive
Pancreatic Cancer
CLDN18.2 positive
Pancreatic Cancer
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login